BioCryst/BCRX

$4.31

-1.6%
-
1D1W1MYTD1YMAX

About BioCryst

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Ticker

BCRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jon Stonehouse

Employees

536

Headquarters

Durham, United States

BioCryst Metrics

BasicAdvanced
$909.12M
Market cap
-
P/E ratio
-$1.18
EPS
1.94
Beta
-
Dividend rate
$909.12M
1.9395
$9.07
$4.27
3.1M
3.307
3.115
-1.11%
-42.46%
-55.84%
2.743
22.37%
11.38%
164.98%

What the Analysts think about BioCryst

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 11 analysts.
220.65% upside
High $30.00
Low $6.00
$4.31
Current price
$13.82
Average price target

BioCryst Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-66.05% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$93.4M
7.73%
Net income
$-61.7M
70.91%
Profit margin
-66.05%
58.66%

BioCryst Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 27.05%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.28
-$0.40
-$0.19
-$0.31
-
Expected
-$0.30
-$0.23
-$0.23
-$0.24
-$0.21
Surprise
-6.3%
75.21%
-18.59%
27.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for BioCryst stock?

BioCryst (BCRX) has a market cap of $909.12M as of April 25, 2024.

What is the P/E ratio for BioCryst stock?

The price to earnings (P/E) ratio for BioCryst (BCRX) stock is 0 as of April 25, 2024.

Does BioCryst stock pay dividends?

No, BioCryst (BCRX) stock does not pay dividends to its shareholders as of April 25, 2024.

When is the next BioCryst dividend payment date?

BioCryst (BCRX) stock does not pay dividends to its shareholders.

What is the beta indicator for BioCryst?

BioCryst (BCRX) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the BioCryst stock price target?

The target price for BioCryst (BCRX) stock is $13.82, which is 228.27% above the current price of $4.21. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell BioCryst stock

Buy or sell BioCryst stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing